

ForPatients

by Roche

Autoimmune Disorder

A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02679014 2015-002864-18
BP29911

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

A randomized, double-blind, placebo-controlled, two treatment, parallel group study to investigate the effects of RO5459072, a cathepsin S inhibitor, on the immune response to a gluten challenge in volunteers with celiac disease. Volunteers with previously diagnosed celiac disease will be randomized to receive either 100 milligrams (mg) RO5459072 or placebo twice daily with food for 28 days (Days 1 to 28).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT02679014 2015-002864-18 BP29911
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years & <= 60 Years

Healthy Volunteers
No
